Ultragenyx stumbles with UX007 PhIII, shares plunge
Rare disease specialist Ultragenyx Pharma $RARE has abandoned its experimental drug, UX007, as a treatment for Glut1 DS – a debilitating disease characterized by seizures, developmental delay, and movement disorders. The drugmaker, whose stock fell sharply in early trading, said the drug failed to demonstrate a statistically significant improvements in a Phase III trial.
UX007, also dubbed triheptanoin, was designed to address glucose transporter type-1 deficiency syndrome — or Glut1 DS — by getting glucose into the brains of the genetically afflicted group. Without adequate glucose, patients have a tendency to suffer from repeated seizures. Roughly 500 cases have been reported worldwide since the disorder was first identified in 1991, according to the NIH.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.